New cholesterol medication now available
Novartis Malaysia, a medicines company, announced on 7 March 2023 that inclisiran an effective and sustained treatment to gain control of low-density lipoprotein cholesterol (LDL-C) is now available.
Inclisiran is an innovative therapy that aids in lowering LDL-C levels in the blood as an add-on to existing cholesterol-lowering treatments and lifestyle modifications. This therapy provides effective and sustained LDL-C reduction, improving patients’ health with only two maintenance doses a year.
Based on the results of ORION-10, a clinical study, the therapy provides an effective LDL-C reduction of up to 52 percent in patients with elevated LDL-C despite already being on maximally tolerated cholesterol-lowering treatment.
Elwakil Mohamed, country president for Novartis Malaysia, said: “[The drug] helps medical professionals treat individuals who have high cholesterol despite treatment with maximally tolerated statins. It offers a combination of a convenient twice-a-year maintenance dosing schedule, as well as the ability to be used in primary care and provide sustained reductions in LDL-C is a hugely positive milestone in patient care. We at Novartis Malaysia are committed to treating hypercholesterolaemia—or high blood cholesterol levels—with new innovative therapies.”